Fortrea Holdings Inc. (FTRE) - 10-Q Summary
Business Context and Reporting Period
Company: Fortrea Holdings Inc., a global contract research organization (CRO) providing biopharmaceutical and medical device development solutions.
Reporting Period: Quarterly period ended June 30, 2026 (Q2 2026).
Segment: Single reportable segment: Clinical Services.
Share Count: 95.1 million shares of common stock outstanding as of July 27, 2026.
Key Financial Metrics
| Metric (in millions) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Revenues | $678.2 | $710.3 | $1,314.7 | $1,361.6 |
| Operating Income (Loss) | $14.8 | $(330.3) | $11.4 | $(850.4) |
| Net Loss | $(13.2) | $(374.9) | $(36.8) | $(937.8) |
| Diluted EPS | $(0.14) | $(4.14) | $(0.39) | $(10.37) |
| Cash from Operations (YTD) | $11.9 | $(102.4) | $11.9 | $(102.4) |
| Cash & Equivalents (End of Period) | $168.6 | $81.2 | $168.6 | $81.2 |
| Total Debt (Current + Long-term) | $1,054.3 | $1,052.8 | $1,054.3 | $1,052.8 |
Note: Total Debt calculated as Current portion of long-term debt ($17.1M) + Long-term debt ($1,037.2M).
Material Changes vs. Prior Period
- Revenue Decline: Q2 2026 revenue decreased 4.5% year-over-year (YoY) to $678.2M. Organic revenue declined 4.9% due to lower pass-through costs and reduced demand for Functional Service Provider (FSP) business, partially offset by growth in clinical pharmacology.
- Profitability Improvement: The company returned to operating profitability ($14.8M) in Q2 2026 compared to a significant operating loss of $(330.3)M in Q2 2025. This improvement is primarily driven by the absence of goodwill impairments recorded in the prior year ($309.1M in Q2 2025).
- Cost Reduction: Direct costs decreased 6.6% YoY, and SG&A expenses decreased 18.2% YoY, reflecting lower personnel costs, restructuring benefits, and reduced credit loss provisions.
- Cash Flow Turnaround: Operating cash flow improved significantly to a positive $11.9M for the six months ended June 30, 2026, compared to a use of $102.4M in the prior year period.
Guidance, Outlook, Risks, and Unusual Items
- Backlog: Total backlog stood at $7.8 billion as of June 30, 2026. Management notes that backlog is not a consistent indicator of future revenue due to contract variability and cancellation risks.
- Legal Proceedings (Material Risk): On July 6, 2026, Thermo Fisher Scientific and affiliates filed an action in Delaware Court of Chancery challenging the appointment of CFO Jason Knoblauch, alleging violation of restrictive covenants. A temporary restraining order was issued on July 25, 2026, prohibiting Mr. Knoblauch from performing services. David R. Smith was appointed Interim CFO effective July 27, 2026.
- Shareholder Litigation: A purported class action lawsuit regarding alleged securities law violations (Lucas Deslande v. Fortrea Holdings Inc.) is ongoing; the company filed a motion to dismiss in January 2026.
- Debt Covenants: The company remains in compliance with all financial covenants under its Credit Agreement as of June 30, 2026.
- Unusual Items: No goodwill impairments were recorded in 2026, contrasting with $797.9M in impairments recorded in the first half of 2025.
Investor Verification Checklist
- CFO Transition Impact: Verify the operational and strategic impact of the temporary restraining order on the CFO and the appointment of the interim CFO.
- Revenue Mix: Assess the sustainability of the decline in FSP business demand versus the growth in clinical pharmacology.
- Customer Concentration: Note that one customer accounted for approximately 17.0% of revenue for the six months ended June 30, 2026.
- Debt Servicing: Review the company's ability to service $1.05B in debt with current operating cash flows, noting the effective interest rates on term loans (5.66% and 7.16%).
- Restructuring Progress: Monitor the remaining restructuring accrual of $8.0M and the timeline for completion of cost-saving initiatives.